Fine Structural Design of 3βHSD1 Inhibitors for Prostate Cancer Therapy

Scientists demonstrated the feasibility of using predicted structural models for optimizing lead compounds, and HEAL-116 provides a promising avenue for the clinical validation of 3βHSD1 inhibitors in prostate cancer therapy.